Drug name - Zioptan

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US5886035 AKORN Difluoroprostaglandin derivatives and their use
Dec, 2022

(2 months from now)

CN1187486A AKORN Difluoro-Prostaglandin Derivatives And Methods Of Use
Dec, 2017

(4 years ago)

CN1108289C AKORN Difluoro-Prostaglandin Derivatives And Methods Of Use
Dec, 2017

(4 years ago)

EP850926A3 AKORN Difluoroprostaglandin Derivatives And Their Use
Dec, 2022

(2 months from now)

EP850926A2 AKORN Difluoroprostaglandin Derivatives And Their Use
Dec, 2022

(2 months from now)

EP850926B1 AKORN Difluoroprostaglandin Derivatives And Their Use
Dec, 2022

(2 months from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10864159 AKORN Method and composition for treating ocular hypertension and glaucoma May, 2029

(6 years from now)

US9999593 AKORN Method and composition for treating ocular hypertension and glaucoma May, 2029

(6 years from now)

Drugs and Companies using TAFLUPROST ingredient

Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.0015% SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.